Perspective
Aug. 28, 2014
Inter partes review: a powerful new weapon
The inter partes review, a new proceeding developed under the America Invents Act, is becoming the new weapon of choice for challenging the validity of issued patents. By Michael L. Fuller
The inter partes review (IPR), a new proceeding developed under the America Invents Act (AIA), is becoming the new weapon of choice for challenging the validity of issued patents. Since September of 2012, when the U.S. Patent and Trademark Office first implemented its IPR rules, over 1,500 IPRs have been filed, with about 95 IPRs challenging pharmaceutical and biotechnology patents.
In an IPR, the party chal...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In